| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/27/2005 | US20050020647 Compositions comprising epothilones and their use for the treatment of carcinoid syndrome |
| 01/27/2005 | US20050020639 Novel compounds |
| 01/27/2005 | US20050020614 Stabilization plaque in blood vessels; therapy for restenosis in diabetic patients |
| 01/27/2005 | US20050020607 Mixture of 2-(4'-bromobiphenyl-4-sulfonylamino0-3-methylbutyric acid and atorvastatin ; therapy for vascular disorders |
| 01/27/2005 | US20050020604 5-HT receptor ligands and uses thereof |
| 01/27/2005 | US20050020600 Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| 01/27/2005 | US20050020585 Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| 01/27/2005 | US20050020577 Method of treating lower urinary tract disorders |
| 01/27/2005 | US20050020576 Opioid antagonist; analgesics; antiinflammatory agents; side effect reduction |
| 01/27/2005 | US20050020558 Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics |
| 01/27/2005 | US20050020556 Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes |
| 01/27/2005 | US20050020551 Using a compound containing gonand ring and a keto group |
| 01/27/2005 | US20050020548 Viricides; aids therapy |
| 01/27/2005 | US20050020537 Bioadhesive antibacterial wound healing composition |
| 01/27/2005 | US20050020534 Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites |
| 01/27/2005 | US20050020523 Modified antisense nucleotides complementary to a section of the human haras gene |
| 01/27/2005 | US20050020519 Increase concentration of peptide; controlling glucose uptake into cells; adjust metabolism; stimulate cell proliferation; reduce apoptosis; moderate gene expression' |
| 01/27/2005 | US20050020517 Treatment of HIV infection through combined administration of tipranavir and capravirine |
| 01/27/2005 | US20050020516 Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
| 01/27/2005 | US20050020514 From fermentation of Streptomyces; bactericides |
| 01/27/2005 | US20050020498 Apo-2 ligand/trail formulations |
| 01/27/2005 | US20050020496 Diagnosis, hormone replacement therapy for HIV positive females, gene therapy; metabolic disorders; antidiabetic, anticholesterol, hypoglycemic agents |
| 01/27/2005 | US20050020495 Antiretroviral compositions comprising thymosin alpha peptides and protease inhibitors |
| 01/27/2005 | US20050020482 Methods for modulating gap junctions |
| 01/27/2005 | US20050020480 Administering a steroid |
| 01/27/2005 | US20050019926 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same |
| 01/27/2005 | US20050019921 Method for combined sequential agent delivery and electroporation for cell structures and use thereof |
| 01/27/2005 | US20050019892 Screening process for antibacterial agents |
| 01/27/2005 | US20050019882 Using plant enzymes for the production of flavor, fragrance, pharmaceutical or bio-control agents from less valuable substrates; terpenoid biosynthesis |
| 01/27/2005 | US20050019869 Chimeric neuropeptide Y receptors |
| 01/27/2005 | US20050019837 Using glutamate decarboxylase concentration as diagnostic indicator of autoimmune and connective tissue disorders |
| 01/27/2005 | US20050019835 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 01/27/2005 | US20050019832 IGF-1 receptor interacting proteins |
| 01/27/2005 | US20050019821 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 01/27/2005 | US20050019765 Methods for treating disorders of the nervous and reproductive systems |
| 01/27/2005 | US20050019763 Isolated polypeptide of given sequence; expression vectors, host cells, antibodies, agonists, and antagonists; use in diagnosing, treating, or preventing various disorders |
| 01/27/2005 | US20050019751 Contacting human scavenger receptor class B type I with polypeptide and measuring ability of test compound to inhibit binding; used in treatment and prophylaxis |
| 01/27/2005 | US20050019436 Relieving pain at a body site by administering a dosage of capsaicinoid at the painful site without eliciting an effect outside the discrete location; local anesthetic effect; targeted therapy |
| 01/27/2005 | US20050019431 Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof |
| 01/27/2005 | US20050019429 Administering therapeutically-effective amount of Quercetin or Quercetin Glycosides(extracted from plant source selected from onions and apples) and Epican Forte(mixture of proline, lysine, arginine, vitamin c, n-acetylcystein, selenium, copper, magnesium, manganese) |
| 01/27/2005 | US20050019424 Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives |
| 01/27/2005 | US20050019423 Method for treating amyotrophic lateral sclerosis |
| 01/27/2005 | US20050019417 stabilization of proteins, peptides or cells by fluidization of microparticles to form fluidized bed of microparticles comprising water soluble gel forming solid particles, then spraying coating with liquids comprising sugars and solvents, and drying |
| 01/27/2005 | US20050019386 In mixture of membrane-forming amphiphiles subjected to high pressure homogenization or ultrasound; contain immunomodulator, cyclosporin, and/or at least one cytokine or polyethylene glycol-cytokines |
| 01/27/2005 | US20050019324 Peptides and antibodies to muc 1 proteins |
| 01/27/2005 | US20050019304 Novel human mage-like protein |
| 01/27/2005 | US20050019271 Glycopyrrolate in sustained releae form; antimuscarinic agents |
| 01/27/2005 | US20050019261 Using serine protease inhibitor; contacting brain tissue; analyzing in variations in protease gene expression |
| 01/27/2005 | CA2539190A1 Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor |
| 01/27/2005 | CA2532806A1 Medicinal composition |
| 01/27/2005 | CA2532805A1 Pharmaceutical composition |
| 01/27/2005 | CA2532309A1 Ambroxol for treating acute pains |
| 01/27/2005 | CA2532308A1 Ambroxol for treating epilepsy |
| 01/27/2005 | CA2532304A1 Ambroxol for treating tinnitus |
| 01/27/2005 | CA2532301A1 Ambroxol for treating chronic nociceptive pains |
| 01/27/2005 | CA2532252A1 Treatment of sexual dysfunction |
| 01/27/2005 | CA2532138A1 Injection of bone marrow-derived cells and medium for angiogenesis |
| 01/27/2005 | CA2531322A1 A method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture |
| 01/26/2005 | EP1500403A1 Preventive/remedy for diabetes |
| 01/26/2005 | EP1500402A1 Cell death inhibitor |
| 01/26/2005 | EP1500401A1 Drugs for treating vascular diseases |
| 01/26/2005 | EP1499742A1 Nad)p)h oxidase inhibitors for increased glucose uptake and treatment of type ii diabetes |
| 01/26/2005 | EP1499730A1 Immunoconjugates for the treatment of tumours |
| 01/26/2005 | EP1499729A1 Derivatives of the nf-kappab inducing enzyme, their preparation and use |
| 01/26/2005 | EP1499724A1 Derivatives of the il-2 receptor gamma chain, their production and use |
| 01/26/2005 | EP1499585A1 Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition |
| 01/26/2005 | EP1499392A1 Method and agents for the prevention, inhibition, and therapy of cancers |
| 01/26/2005 | EP1499362A1 Fusions of cytokines and tumor targeting proteins |
| 01/26/2005 | EP1499360A2 Formulation comprising buprenorphine |
| 01/26/2005 | EP1499358A1 Ph-sensitive polymer |
| 01/26/2005 | EP1499357A1 Treatment of metabolic syndrome |
| 01/26/2005 | EP1499356A1 Methods of treatment and diagnosis of patients with hepatitis c infection |
| 01/26/2005 | EP1499354A2 Methods of using cytokine antagonists to treat hiv infection and aids |
| 01/26/2005 | EP1499343A1 A method of modulating cellular activity |
| 01/26/2005 | EP1499342A2 Therapeutic composition for treatment of cancer by arginine depletion |
| 01/26/2005 | EP1499334A2 Use of compositions containing petasites for treating diseases |
| 01/26/2005 | EP1499331A2 Salt solution for colon cleansing |
| 01/26/2005 | EP1499325A1 Methods and compositions for inhibition of irritation by disaccharide and metal ions |
| 01/26/2005 | EP1499324A1 Method for treating and preventing hyperparathyroidism |
| 01/26/2005 | EP1499321A2 Methods for increasing the therapeutic response to electroconvulsive therapy ("ect") |
| 01/26/2005 | EP1499317A1 Treatment of diabetes and diabetic complications with nhe-1 inhibitors |
| 01/26/2005 | EP1499316A1 (1-4-piperidinyl)benzimidazole derivatives useful as histamine h3 antagonists |
| 01/26/2005 | EP1499315A1 Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia |
| 01/26/2005 | EP1499311A1 Substituted benzazoles and use thereof as raf kinase inhibitors |
| 01/26/2005 | EP1499309A1 Prevention and treatment of functional somatic disorders, including stress-related disorders |
| 01/26/2005 | EP1499305A2 Use of ep4 receptor ligands in the treatment of il-6 involved diseases |
| 01/26/2005 | EP1499303A2 Multi-phase, multi-compartment capsular system |
| 01/26/2005 | EP1499294A2 Transport system in biological systems |
| 01/26/2005 | EP1499293A2 Topical application of alpha-dfmo and anti-inflammatory drug for treatment of actinic keratoses |
| 01/26/2005 | EP1499290A1 Warming and nonirritating lubricant compositions |
| 01/26/2005 | EP1499289A2 Volume efficient controlled release dosage form |
| 01/26/2005 | EP1499284A1 Biologically active compounds for the modification of bodily odours |
| 01/26/2005 | EP1499277A2 Modification of feeding behavior |
| 01/26/2005 | EP1499187A2 Immunostimulatory g,u-containing oligoribonucleotides |
| 01/26/2005 | EP1430140A4 Isoform-selective inhibitors and activators of pde3 cyclic |
| 01/26/2005 | EP1278749B1 USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS |
| 01/26/2005 | EP1276504B1 Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent |
| 01/26/2005 | EP1248629B1 Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs |
| 01/26/2005 | EP1239867B1 Methods for treating and preventing damage to mucosal tissue |
| 01/26/2005 | EP1233752B1 Radiation sensitive liposomes |